These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22412061)

  • 1. Cost-effectiveness and population outcomes of general population screening for hepatitis C.
    Coffin PO; Scott JD; Golden MR; Sullivan SD
    Clin Infect Dis; 2012 May; 54(9):1259-71. PubMed ID: 22412061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
    PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic model of a birth cohort screening program for hepatitis C virus.
    McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
    Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
    Urbanus AT; van Keep M; Matser AA; Rozenbaum MH; Weegink CJ; van den Hoek A; Prins M; Postma MJ
    PLoS One; 2013; 8(8):e70319. PubMed ID: 23950920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.
    Barocas JA; Tasillo A; Eftekhari Yazdi G; Wang J; Vellozzi C; Hariri S; Isenhour C; Randall L; Ward JW; Mermin J; Salomon JA; Linas BP
    Clin Infect Dis; 2018 Aug; 67(4):549-556. PubMed ID: 29420742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M; Keeshin SW; Mailliard M; Wilson FA
    JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
    Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A; San Miguel R; Mar J
    Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
    Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
    Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.
    Marcellusi A; Mennini FS; Andreoni M; Kondili LA;
    Eur J Health Econ; 2024 Sep; 25(7):1261-1273. PubMed ID: 38280068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
    Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
    Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
    Jülicher P; Chulanov VP; Pimenov NN; Chirkova E; Yankina A; Galli C
    PLoS One; 2019; 14(7):e0219687. PubMed ID: 31310636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.